FGF2 Transtympanic Delivery for Cochlear Synaptopathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of FDA-approved pharmacological therapies for sensorineural hearing loss (SNHL) that effectively address cochlear synaptopathy, leading to compromised word recognition and other perceptual abnormalities, with current treatments like hearing aids and cochlear implants having limited efficacy.
Innovation Solution
Administering Fibroblast Growth Factor 2 (FGF2) via localized, minimally invasive transtympanic delivery to the inner ear to promote synaptic and neurite regeneration in subjects with SNHL, using a therapeutically effective amount to treat cochlear synaptopathy and improve word recognition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hearing aids and cochlear implants are used to treat sensorineural hearing loss, then hearing assistance is provided, but word recognition remains compromised and efficacy is limited
Solution Approach 1:
The patent replaces mechanical hearing assistance devices (hearing aids and cochlear implants) with a biological therapy using FGF2 protein administration. This substitution transitions from mechanical/electrical systems to a biochemical mechanism that promotes synaptic regeneration and neurite outgrowth, potentially restoring natural neural function rather than bypassing it with devices.
2Reliability
If FGF2 is administered to promote synaptic regeneration, then word recognition and synaptic connections improve, but the complexity of pharmacological therapy increases
Solution Approach 1:
The patent uses FGF2 protein as a biochemical intermediary to mediate between the administered therapy and the target neural structures. The FGF2 acts as a signaling molecule that binds to receptors on neurons and glial cells, triggering intracellular cascades that promote synaptic regeneration and neurite outgrowth, thereby serving as a bridge between external treatment and internal repair mechanisms.
Solution Approach 2:
The patent employs controlled administration of FGF2 at specific dosages (e.g., 10-50 μg per administration) and frequencies (e.g., once weekly for 4-8 weeks) to optimize therapeutic effect. The treatment protocol includes specific concentration ranges (1-100 μg/mL) and delivery parameters that are carefully adjusted to maximize synaptic regeneration while minimizing potential side effects, representing precise parameter control.
3Adaptability or versatility
If current pharmacological therapies are developed for SNHL, then treatment options increase, but none currently address cochlear synaptopathy effectively
Solution Approach 1:
The patent targets specific cell types and locations within the cochlea through localized FGF2 administration. The therapy specifically affects spiral ganglion neurons, inner hair cells, and their synaptic connections, promoting neurite outgrowth and synaptogenesis in the affected regions while leaving other cochlear structures unchanged. This localized action addresses cochlear synaptopathy specifically rather than providing a general hearing loss treatment.
Data Source
AI summary
Methods of using Fibroblast growth factor 2 (FGF2) to treat subjects with hearing loss associated with impaired word recognition.